Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

Haematologica

Volumn 98, Issue 1, 2013, Pages 103-108

  Chase, Andrew ^a   Bryant, Catherine ^a   Score, Joannah ^a   Cross, Nicholas C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; PONATINIB;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 8P; COLONY FORMATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE DISORDER; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AGED; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; PYRIDAZINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84872087188     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066407     Document Type: Article

References (19)

1. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008;119(4):199-206.
2. Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with Tlymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 2011;96(6): 922-6.
3. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5(3): 287-98.
4. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007;110(10):3729-34.
5. Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101(40):14479-84.
6. Wakim JJ, Tirado CA, Chen W, Collins R. t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res. 2011;35(9):e151-3.
7. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 2004;18(5):962-6.
8. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multi-targeted panFGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012;11(3):690-9
9. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10(6):1028-35.
10. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-12.
11. Smedley D, Demiroglu A, Abdul-Rauf M, Heath C, Cooper C, Shipley J, et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia. 1999;1(4):349-55.
12. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98(13):3778-83.
13. Sohal J, Chase A, Goldman JM, Cross NC. Assignment of ZNF262 to human chromosome band 1p34-->p32 by in situ hybridization. Cytogenet Cell Genet. 1999;85(3-4):306-7.
14. Sohal J, Chase A, Mould S, Corcoran M, Oscier D, Iqbal S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Gene Chromosome Canc. 2001;32(2):155-63.
15. Shah NP. Ponatinib: Targeting the T315I Mutation in Chronic Myelogenous Leukemia. Clin Adv Hematol Oncol. 2011; 9(12):925-6.
16. Speidel D, Stocking C. Caspase 3 activity in whole cell extracts of Ba/F3 cells is unrelated to apoptosis. Cell Cycle. 2010;9(18): 3823-5.
17. Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 2006;108 (13):4202-4.
18. Barge RM, Dorrestijn J, Falkenburg JH, Willemze R, Maassen JA. Unconventional rapid Erk1,2 activation is indispensable for proliferation of the growth factor-independent myeloid leukemic cell line KG1. Leukemia. 1998;12(5):699-704.
19. Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26(7):1693-5.